Edition:
United States

Foamix Pharmaceuticals Ltd (FOMX.OQ)

FOMX.OQ on NASDAQ Stock Exchange Global Market

6.20USD
15 Dec 2017
Change (% chg)

$0.26 (+4.38%)
Prev Close
$5.94
Open
$5.99
Day's High
$6.20
Day's Low
$5.90
Volume
90,708
Avg. Vol
24,945
52-wk High
$11.26
52-wk Low
$4.03

Chart for

About

Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and... (more)

Overall

Beta: --
Market Cap(Mil.): $232.09
Shares Outstanding(Mil.): 37.43
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 198.20 16.04
EPS (TTM): -- -- --
ROI: -- -11.76 34.69
ROE: -- -36.72 15.46

BRIEF-Foamix Q3 loss per share $0.47

* Foamix reports third quarter 2017 financial results and provides business update

Nov 15 2017

BRIEF-Foamix Q2 loss per share $0.44

* Foamix reports second quarter 2017 financial results and provides business update

Aug 08 2017

BRIEF-Foamix says expects to report top-line results from study FX2017-22 by mid-2018​

* Foamix announces dosing of first patient in third phase 3 acne study for minocycline foam fmx101

Aug 03 2017

BRIEF-Foamix Pharmaceuticals appoints David Domzalski as CEO

* Foamix Pharmaceuticals appoints David Domzalski as chief executive officer

Jun 29 2017

Earnings vs. Estimates